This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 5, 2012 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the
United Kingdom's National Institute for Health and Clinical Excellence (NICE) has accepted for consideration additional data in the form of an appendix to Alimera's comments on the preliminary Appraisal Consultation Document (ACD) previously issued by NICE for the ILUVIEN
® Single Technology Appraisal (STA).
NICE's Appraisal Committee, which issued the preliminary ACD in August, is currently evaluating the cost-effectiveness of ILUVIEN for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
September 4, 2012, NICE informed Alimera that the Appraisal Committee required adequate time to thoroughly review the additional data. Therefore, the Second Appraisal Committee meeting, previously scheduled for
September 11, 2012, has been rescheduled for
October 11, 2012. According to NICE's Guide to the STA, new data is only accepted if it is likely to affect the provisional recommendations in the ACD.
As Alimera was drafting its response to the ACD, the company determined that ILUVIEN was more cost-effective in a pseudophakic patient subgroup of Alimera's FAME™ Study, providing additional support to its ACD response submission. As a result of diabetes, age or previous DME treatments, each patient in this subgroup had an artificial lens in his or her eye at the start of the study. Patients with an artificial lens cannot further develop a cataract in the treated eye due to their exposure to the corticosteroid delivered via ILUVIEN. These patients will not experience the transient reduction in visual acuity as the result of cataract development that occurred in some patients during the first two years of the FAME Study, nor will they incur the cost associated with cataract surgery.